Oncology
2 drugs are in development for Bladder (Urothelial, Transitional Cell) Cancer.
- Companies
- 2
- Clinical trials
- 6
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Bladder (Urothelial, Transitional Cell) Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| ndv-01 | RELMADA THERAPEUTICS, INC. (RLMD) |
Phase 1(1)
| Drug | Company |
|---|---|
| ugn-501 | UroGen Pharma Ltd. (URGN) |
About this indication
Bladder (Urothelial, Transitional Cell) Cancer context
Oncology·MeSH: Urinary Bladder Neoplasms (D001749)
Narrower concept of MeSH descriptor Urinary Bladder Neoplasms
Prevalence
41.9 / 100K
Incidence
7.4 / 100K/yr
Frequently asked questions
How many drugs are in development for Bladder (Urothelial, Transitional Cell) Cancer?
BioSniper tracks 2 drugs in development for Bladder (Urothelial, Transitional Cell) Cancer across 2 companies.
How many clinical trials target Bladder (Urothelial, Transitional Cell) Cancer?
There are 6 clinical trials targeting Bladder (Urothelial, Transitional Cell) Cancer tracked by BioSniper.
What is the prevalence of Bladder (Urothelial, Transitional Cell) Cancer?
The estimated prevalence of Bladder (Urothelial, Transitional Cell) Cancer is approximately 41.9 per 100,000 population.